Long Term Debt Summary of RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.'s latest annual long term debt in 2022 was 1.4 Million USD , up 23.38% from previous year.
RegeneRx Biopharmaceuticals, Inc.'s latest quarterly long term debt in 2023 Q3 was - USD , down 0.0% from previous quarter.
RegeneRx Biopharmaceuticals, Inc. reported annual long term debt of 1.13 Million USD in 2021, up 19.5% from previous year.
RegeneRx Biopharmaceuticals, Inc. reported annual long term debt of 951.58 Thousand USD in 2020, up 34.39% from previous year.
RegeneRx Biopharmaceuticals, Inc. reported quarterly long term debt of 279.68 Thousand USD for 2023 Q1, down -80.06% from previous quarter.
RegeneRx Biopharmaceuticals, Inc. reported quarterly long term debt of - USD for 2023 Q2, down -100.0% from previous quarter.

Annual Long Term Debt Chart of RegeneRx Biopharmaceuticals, Inc. (2022 - 1995)

Historical Annual Long Term Debt of RegeneRx Biopharmaceuticals, Inc. (2022 - 1995)

Year	Long Term Debt	Long Term Debt Growth
2022	1.4 Million USD	23.38%
2021	1.13 Million USD	19.5%
2020	951.58 Thousand USD	34.39%
2019	708.07 Thousand USD	0.0%
2018	- USD	-100.0%
2017	43.81 Thousand USD	-91.44%
2016	512.02 Thousand USD	-25.67%
2015	688.85 Thousand USD	21.7%
2014	566.02 Thousand USD	30.86%
2013	432.54 Thousand USD	56.95%
2012	275.59 Thousand USD	0.0%
2011	- USD	0.0%
2010	- USD	0.0%
2009	- USD	0.0%
2008	- USD	0.0%
2007	- USD	0.0%
2006	- USD	0.0%
2005	- USD	0.0%
2004	- USD	0.0%
2003	- USD	0.0%
2002	- USD	0.0%
2001	- USD	0.0%
2000	- USD	0.0%
1999	- USD	0.0%
1998	- USD	0.0%
1997	- USD	0.0%
1996	- USD	0.0%
1995	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2023 Q3	- USD	0.0%
2023 Q1	279.68 Thousand USD	-80.06%
2023 Q2	- USD	-100.0%
2022 Q2	1.25 Million USD	4.92%
2022 FY	1.4 Million USD	23.38%
2022 Q4	1.4 Million USD	3.5%
2022 Q1	1.19 Million USD	5.11%
2022 Q3	1.35 Million USD	8.09%
2021 Q3	1.07 Million USD	3.15%
2021 Q4	1.13 Million USD	5.51%
2021 FY	1.13 Million USD	19.5%
2021 Q2	1.04 Million USD	4.67%
2021 Q1	998.16 Thousand USD	4.89%
2020 Q2	858.89 Thousand USD	15.52%
2020 Q1	743.48 Thousand USD	5.0%
2020 FY	951.58 Thousand USD	34.39%
2020 Q4	951.58 Thousand USD	8.75%
2020 Q3	875.02 Thousand USD	1.88%
2019 FY	708.07 Thousand USD	0.0%
2019 Q1	315.98 Thousand USD	0.0%
2019 Q2	636.46 Thousand USD	101.42%
2019 Q3	672.26 Thousand USD	5.63%
2019 Q4	708.07 Thousand USD	5.33%
2018 Q1	- USD	-100.0%
2018 FY	- USD	-100.0%
2018 Q2	- USD	0.0%
2018 Q3	- USD	0.0%
2018 Q4	- USD	0.0%
2017 FY	43.81 Thousand USD	-91.44%
2017 Q4	43.81 Thousand USD	-92.74%
2017 Q3	603.89 Thousand USD	5.4%
2017 Q1	542.31 Thousand USD	5.92%
2017 Q2	572.93 Thousand USD	5.65%
2016 Q2	750.1 Thousand USD	4.26%
2016 Q1	719.47 Thousand USD	4.45%
2016 Q4	512.02 Thousand USD	-34.45%
2016 FY	512.02 Thousand USD	-25.67%
2016 Q3	781.06 Thousand USD	4.13%
2015 FY	688.85 Thousand USD	21.7%
2015 Q2	626.93 Thousand USD	5.14%
2015 Q1	596.3 Thousand USD	5.35%
2015 Q4	688.85 Thousand USD	4.71%
2015 Q3	657.89 Thousand USD	4.94%
2014 Q3	235.06 Thousand USD	15.17%
2014 FY	566.02 Thousand USD	30.86%
2014 Q4	566.02 Thousand USD	140.8%
2014 Q2	204.09 Thousand USD	17.65%
2014 Q1	173.47 Thousand USD	-59.89%
2013 Q3	400.94 Thousand USD	36.59%
2013 Q1	278.93 Thousand USD	1.21%
2013 FY	432.54 Thousand USD	56.95%
2013 Q2	293.53 Thousand USD	5.23%
2013 Q4	432.54 Thousand USD	7.88%
2012 Q4	275.59 Thousand USD	0.0%
2012 FY	275.59 Thousand USD	0.0%
2012 Q3	- USD	0.0%
2012 Q1	- USD	0.0%
2012 Q2	- USD	0.0%
2011 Q3	- USD	0.0%
2011 Q4	- USD	0.0%
2011 FY	- USD	0.0%
2011 Q1	- USD	0.0%
2011 Q2	- USD	0.0%
2010 Q1	- USD	0.0%
2010 Q4	- USD	0.0%
2010 Q2	- USD	0.0%
2010 Q3	- USD	0.0%
2010 FY	- USD	0.0%
2009 Q3	- USD	0.0%
2009 FY	- USD	0.0%
2009 Q4	- USD	0.0%
2009 Q2	- USD	0.0%
2009 Q1	- USD	0.0%
2008 Q2	- USD	0.0%
2008 Q1	- USD	0.0%
2008 FY	- USD	0.0%
2008 Q4	- USD	0.0%
2008 Q3	- USD	0.0%
2007 Q4	- USD	0.0%
2007 FY	- USD	0.0%
2007 Q2	- USD	0.0%
2007 Q3	- USD	0.0%
2007 Q1	- USD	0.0%
2006 Q3	- USD	0.0%
2006 Q4	- USD	0.0%
2006 FY	- USD	0.0%
2006 Q1	- USD	0.0%
2006 Q2	- USD	0.0%
2005 Q3	- USD	0.0%
2005 Q4	- USD	0.0%
2005 Q2	- USD	0.0%
2005 Q1	- USD	0.0%
2005 FY	- USD	0.0%
2004 Q4	- USD	0.0%
2004 FY	- USD	0.0%
2004 Q3	- USD	0.0%
2004 Q2	- USD	0.0%
2004 Q1	- USD	0.0%
2003 Q3	- USD	0.0%
2003 Q4	- USD	0.0%
2003 Q1	- USD	0.0%
2003 Q2	- USD	0.0%
2003 FY	- USD	0.0%
2002 FY	- USD	0.0%
2002 Q4	- USD	0.0%
2002 Q3	- USD	0.0%
2002 Q2	- USD	0.0%
2002 Q1	- USD	0.0%
2001 FY	- USD	0.0%
2001 Q4	- USD	0.0%
2001 Q3	- USD	0.0%
2001 Q2	- USD	0.0%
2001 Q1	- USD	0.0%
2000 Q2	- USD	0.0%
2000 FY	- USD	0.0%
2000 Q1	- USD	0.0%
2000 Q3	- USD	0.0%
2000 Q4	- USD	0.0%
1999 FY	- USD	0.0%
1999 Q4	- USD	0.0%
1998 Q1	- USD	0.0%
1998 FY	- USD	0.0%
1998 Q4	- USD	0.0%
1998 Q2	- USD	0.0%
1997 Q1	- USD	0.0%
1997 Q3	- USD	0.0%
1997 Q4	- USD	0.0%
1997 Q2	- USD	0.0%
1997 FY	- USD	0.0%
1996 Q3	- USD	0.0%
1996 Q1	- USD	0.0%
1996 Q2	- USD	0.0%
1996 FY	- USD	0.0%
1996 Q4	- USD	0.0%
1995 FY	- USD	0.0%

Peer Long Term Debt Comparison of RegeneRx Biopharmaceuticals, Inc.

Name	Long Term Debt	Long Term Debt Difference
Burzynski Research Institute, Inc.	- USD	-Infinity%
Arch Therapeutics, Inc.	- USD	-Infinity%
Evofem Biosciences, Inc.	8000.00 USD	-17436.675%
Nascent Biotech, Inc.	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
Santhera Pharmaceuticals Holding AG	1.75 Million USD	20.083%
Qrons Inc.	80 Thousand USD	-1653.668%
Adynxx, Inc.	- USD	-Infinity%
Neon Bloom, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	20.31 Million USD	93.093%
ProtoKinetix, Incorporated	- USD	-Infinity%
Skye Bioscience, Inc.	171.23 Thousand USD	-719.327%
Eiger BioPharmaceuticals, Inc.	- USD	-Infinity%
Nanobac Pharmaceuticals, Incorporated	- USD	-Infinity%
Institute of Biomedical Research Corp.	- USD	-Infinity%
SQZ Biotechnologies Company	20.9 Million USD	93.29%
Intellipharmaceutics International Inc.	- USD	-Infinity%
Propanc Biopharma, Inc.	58.64 Thousand USD	-2292.371%
Mesoblast Limited	100.29 Million USD	98.601%
Marizyme, Inc.	667.12 Thousand USD	-110.294%
Genus plc	228.2 Million USD	99.385%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
Pharming Group N.V.	166.1 Million USD	99.155%
Therapeutic Solutions International, Inc.	5512.00 USD	-25352.358%
CNBX Pharmaceuticals Inc.	- USD	-Infinity%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
ContraFect Corporation	2.21 Million USD	36.519%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
IMV Inc.	27.39 Million USD	94.88%
AXIM Biotechnologies, Inc.	5.42 Million USD	74.147%
MultiCell Technologies, Inc.	36.43 USD	-3850940.351%
ONE Bio Corp.	592.19 Thousand USD	-136.903%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	55.61 Million USD	97.477%
Arno Therapeutics, Inc.	- USD	-Infinity%
EV Biologics, Inc.	- USD	-Infinity%
Q BioMed Inc.	- USD	-Infinity%
Emmaus Life Sciences, Inc.	2.22 Million USD	36.975%
Mosaic ImmunoEngineering Inc.	1.22 Million USD	-14.212%
Biomind Labs Inc.	- USD	-Infinity%
American Oriental Bioengineering, Inc.	554.59 Thousand USD	-152.968%
Provectus Biopharmaceuticals, Inc.	25.29 Thousand USD	-5445.413%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
Oncotelic Therapeutics, Inc.	1.89 Million USD	26.102%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Acro Biomedical Co., Ltd.	- USD	-Infinity%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	322 Thousand USD	-335.694%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
CSL Limited	11.23 Billion USD	99.988%
Wesana Health Holdings Inc.	- USD	-Infinity%
Halberd Corporation	150 Thousand USD	-835.289%
Enzolytics Inc.	- USD	-Infinity%
Agentix Corp.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Nuo Therapeutics, Inc.	164.2 Thousand USD	-754.38%
MetaStat, Inc.	- USD	-Infinity%
argenx SE	15.35 Million USD	90.863%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	- USD	-Infinity%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	- USD	-Infinity%
Zenith Capital Corp.	4456.00 USD	-31384.156%
Genscript Biotech Corporation	287.12 Million USD	99.511%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	126.3 Thousand USD	-1010.777%
WPD Pharmaceuticals Inc.	229.29 Thousand USD	-511.857%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
Kadimastem Ltd	229.69 Thousand USD	-510.792%
Helix BioMedix, Inc.	- USD	-Infinity%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Capstone Therapeutics Corp.	8.26 Million USD	83.024%
BioStem Technologies, Inc.	265.63 Thousand USD	-428.144%
Oncology Pharma Inc.	- USD	-Infinity%
Reve Technologies, Inc.	1064.00 USD	-131754.699%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
Regen BioPharma, Inc.	149.61 Thousand USD	-837.702%
Regen BioPharma, Inc.	149.61 Thousand USD	-837.702%
NovAccess Global Inc.	- USD	-Infinity%
Affymax, Inc.	- USD	-Infinity%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
CytoDyn Inc.	141 Thousand USD	-894.989%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Alseres Pharmaceuticals, Inc.	7.81 Million USD	82.06%
SYBLEU INC	300 Thousand USD	-367.645%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	369.04 Thousand USD	-280.148%
International Stem Cell Corporation	445 Thousand USD	-215.266%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	8.15 Million USD	82.786%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	457 Thousand USD	-206.988%
Neutra Corp.	- USD	-Infinity%
Windtree Therapeutics, Inc.	1.16 Million USD	-20.838%
PureTech Health plc	18.25 Million USD	92.313%
Coeptis Therapeutics, Inc.	150 Thousand USD	-835.289%
IXICO plc	275 Thousand USD	-410.158%
IntelGenx Technologies Corp.	11.83 Million USD	88.15%
Gelesis Holdings, Inc.	26.3 Million USD	94.667%
CSL Limited	11.23 Billion USD	99.988%
Cellectis S.A.	36.21 Million USD	96.126%

Global Stocks Search

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Long Term Debt Summary of RegeneRx Biopharmaceuticals, Inc.

Annual Long Term Debt Chart of RegeneRx Biopharmaceuticals, Inc. (2022 - 1995)

Historical Annual Long Term Debt of RegeneRx Biopharmaceuticals, Inc. (2022 - 1995)

Peer Long Term Debt Comparison of RegeneRx Biopharmaceuticals, Inc.